Parion Sciences Announces Initiation of Phase 2 Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Parion Sciences Announces Initiation of Phase 2 Clinical Study of P-1037 for the Treatment of Cystic Fibrosis

DURHAM, N.C., May 6, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has begun enrollment of a phase 2 clinical trial of P-1037 in patients with Cystic Fibrosis (CF).

The trial has been named the "CLEAN-CF" trial which refers to "Clearing Lungs with ENaC inhibition in Cystic Fibrosis". The CLEAN-CF study will include CF patients regardless of an individual's genetic mutation. Inhibiting the epithelial sodium channels (ENaC) in the airways with P-1037, an "ENaC blocker," is expected to re-hydrate the mucus layers, thus restoring airway clearance, improve lung function and, ultimately, reduce exacerbations. P-1037 has demonstrated to be long acting in preclinical models and to have a favorable safety and tolerability profile in the completed Phase 1 studies. The initiation of the Phase 2 clinical trials was supported by an award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation.

Parion expects to enroll approximately 120 patients at 30 sites, most within CFFT's clinical trials national network. "With P-1037 we look forward to the potential of having a novel therapy that is effective for people with cystic fibrosis regardless of their specific genotype," said Dr. Scott Donaldson, Associate Professor of Medicine at the University of North Carolina, Chapel Hill and Co-Primary Investigator for the CLEAN-CF Trial.

CF is a rare genetic disease affecting approximately 30,000 individuals in the US and 70,000 world-wide. CF is caused by a gene mutation and its protein product, called CFTR, and the inability of the epithelial cells of the lung to provide sufficient fluid to the mucus layer. Mucus hydration is maintained by the balance of airway ion transport that regulates fluid secretion (hydrating) and fluid absorption (dehydrating).

"Initiating this phase 2 study in CF represents a major milestone for Parion as we continue on our mission to advance our first-in-class therapy to treat all CF patients," said Paul Boucher, President of Parion. "The Parion team, our partners and the participating clinical sites, combined with Cystic Fibrosis Foundation Therapeutics' support, have worked expeditiously to achieve this milestone as we now focus towards enrolling patients."

For a list of specific clinical sites that will be enrolling the CLEAN-CF trial, please refer to the following link on ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT02343445?term=p-1037

About ENaC Inhibitors and P-1037

Epithelial sodium channel (ENaC) inhibitors are designed to block the sodium channels on the airway surfaces. In pulmonary diseases where there is a build-up of excessively concentrated mucus, such as cystic fibrosis and chronic obstructive pulmonary disease, preclinical models have demonstrated that blocking the ENaC channel diminishes fluid absorption allowing the mucus layers to be hydrated for longer periods of time. Hydration of mucosal surfaces restores airway clearance, reducing infection and improving lung function. P-1037 is a novel, long acting ENaC inhibitor that demonstrated a superior safety profile versus other known ENaC inhibitors in both pre-clinical and Phase 1 studies.

About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and leverages our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com .

Paul Boucher President, Parion Sciences 919-313-1195

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 144

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 0

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 90

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 43

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 118

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 21

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 151

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 96

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 40

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading

Top 5 Most Recently Viewed Articles

Redwire Corp's Exciting NASA Contract Boosts RDW Stock

Updated Category News Views 291

Recent Developments with Redwire Corp (RDW) Redwire Corp shares have recently experienced a notable increase following the announcement of a new contract with NASA. This contract marks an exciting milestone for the company as it seeks to enhance its role in space exploration and biotechnology. Details of the NASA Contract Redwire has been awarded an...

Continue Reading
Exploring the RWA Tokenization and Its Financial Impact

Updated Category News Views 442

CoinEx Research Explores the Evolution of RWA Tokenization CoinEx Research, part of the prominent crypto exchange CoinEx, has launched an insightful two-part report titled “Unlocking the On-Chain Asset Era: A Deep Dive into the Real World Asset (RWA) Tokenization Revolution.” This comprehensive analysis ventures deep into the burgeoning landscape of RWAs, exploring...

Continue Reading
Transforming $1000 into Nearly $10,000: RJF's Growth Journey

Updated Category News Views 213

Unveiling the Growth of Raymond James Financial Inc. Investors often look for robust opportunities that can yield significant returns over time. Raymond James Financial Inc. (NYSE: RJF) has proven to be one such opportunity. Over the past 20 years, RJF has consistently outperformed the market, generating a remarkable average annual return of 12.05%. With a current market...

Continue Reading
Aequum Capital Unlocks $250 Million Financing for Expansion

Updated Category News Views 193

Aequum Capital Unlocks $250 Million Financing for Expansion Aequum Capital Financial, LLC, a rapidly growing specialty finance lender backed by Castlelake, L.P., recently announced a groundbreaking achievement. The company has successfully closed a $250 million debt facility in collaboration with Wells Fargo & Company (NYSE: WFC). This pivotal financing marks a...

Continue Reading
Market Insights: DAX and USD/JPY Trends Worth Noticing

Updated Category News Views 176

Focus on DAX Amid Economic Stagnation The DAX index is currently navigating through a steady phase amid stagnant economic signals. Its performance is largely affected by anticipation regarding upcoming U.S. economic data and evolving conditions within Germany's economy. Stagnation in German GDP Recently, German GDP has shown no growth, remaining at 0% quarter-on-quarter....

Continue Reading